NCT01913119View on ClinicalTrials.gov

A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Histologically Proven Extranodal NKTcell Lymphoma
Interventions
DRUG

Romidepsin

"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"

Trial Locations (4)

410-769

National Cancer Center, Goyang-si

139-709

Korea Cancer Center Hospital, Nowon-gu

120-752

Severance Hospital, Seodaemun-gu

138-736

Asan Medical Center, Songpa-gu

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Samsung Medical Center

OTHER